An observational study in Multiple Myeloma, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by iOMEDICO AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 297 studies in Multiple Myeloma with a site in Germany — 49 open to participants now, 102 under way, 47 of them phase 3. Multiple Myeloma · Germany.
Among the 297 studies in Multiple Myeloma with a site in Germany, this one is the 4th largest by planned enrollment of the 32 observational ones that give a count, is one of 16 that started in 2017, is one of 32 observational ones, reaches primary completion later than 36 of the 101 other live ones, and was the 164th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →49 of the 297 studies in Multiple Myeloma with a site in Germany are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 15 more countries
Ages 18–130
CSL Behring · Sites in Germany, United States, Belgium and 8 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Germany, Australia, Czechia and 11 more countries
Ages 18+
Technical University of Munich · Sites in Germany
Ages 18–99
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
297 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 109 · Phase 3 113
First in 1997; this study’s year is marked. 16 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,200 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 171 across the 263 interventional studies, 298 across the 32 observational. Of the 180 that completed or were terminated, 87 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
212 of 297 have an industry lead sponsor. The 10 most frequent:
iOMEDICO AG is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
iOMEDICO AG has 9 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
23 of the studies in Multiple Myeloma with a site in Germany that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
Add all 23 to your calendar (.ics) → With an account.
Among the 297 studies in Multiple Myeloma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated for up to five years.
Adult patients with multiple myeloma (MM) requiring systemic treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physician's choice according to patient's needs.
Course of treatment (treatment reality)
Documentation of anamnestic data and therapy sequences
Time frame: 5 years per patient
Best Response
Documentation of response rates per line of treatment.
Time frame: 5 years per patient
Progression-free survival
Documentation of progression-free survival per line of treatment.
Time frame: 5 years per patient
Overall survival
Documentation of overall survival time.
Time frame: 5 years per patient
Health-related quality of life (Patient-reported outcome)
EORTC QLQ-C30 core questionnaire.
Time frame: 5 years per patient
Myeloma-specific health-related quality of life (Patient-reported outcome)
EORTC QLQ-MY20, the myeloma specific module.
Time frame: 5 years per patient
Quality of life (Patient-reported outcome)
Brief Pain Inventory (BPI)
Time frame: 5 years per patient
Plan to share: No
Started Sep 2017 (actual). Primary completion is estimated for Dec 2026, 111 months after the start.
Of 66 industry-sponsored observational studies under Multiple Myeloma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 70. This study's planned 111 months is above that.
Counting every sponsor, half of 239 studies reached it within 61 months; a quarter within 30 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.